Intensity Therapeutics (Intensity Therapeutics) Interest Expense : $-0.22 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Intensity Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Intensity Therapeutics's interest expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.22 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Intensity Therapeutics's Operating Income for the three months ended in Mar. 2024 was $ -4.74 Mil. Intensity Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $ 0.00 Mil. GuruFocus does not calculate Intensity Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Intensity Therapeutics Interest Expense Historical Data

The historical data trend for Intensity Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intensity Therapeutics Interest Expense Chart

Intensity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.02

-0.08

-0.31

Intensity Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial											-0.08	-0.22	-	-	-

Intensity Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.22 Mil.

Intensity Therapeutics (NAS:INTS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Intensity Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-4.74 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.13 Mil.

Intensity Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

GuruFocus does not calculate Intensity Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Intensity Therapeutics (Intensity Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intensity Therapeutics Inc (NAS:INTS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

61 Wilton Road, 3rd Floor, Westport, CT, USA, 06880

Website

https://www.intensitytherapeutics.com

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors.

Executives

Emer Leahy	director	1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH FL 33139
Daniel Donovan	director	712 VISTA BLVD #305, WACONIA MN 55387
James M Ahlers	officer: Executive VP of CF	2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Lewis H Bender	director, 10 percent owner, officer: President and CEO	765 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Mark A Goldberg	director	PERCEPTIVE INFORMATICS INC, 200 WEST STREET, WALTHAM MA 02451
John M Wesolowski	officer: Interim CFO	61 WILTON ROAD, 3RD FLOOR, WESTPORT CT 06880